Johnson & Johnson enters third phase COVID-19 vaccine trial

Pfizer now says its COVID-19 vaccine is 95% effective in late-stage trials with no serious side effects. Pfizer says it plans to seek emergency authorization within days for use of the vaccine from the Food and Drug Administration. On Monday, Moderna reported that its vaccine is 94.5% effective.

Johnson & Johnson, another pharmaceutical company, is recruiting volunteers for its third-phase COVID-19 vaccine clinical trial. Rutgers Robert Wood Johnson Medical School was chosen as a clinical trial site. Correspondent Leah Mishkin reports.